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Abstract
Background: To identify a simple decision tree using early symptom change to predict response to atypical
antipsychotic therapy in patients with (Diagnostic and Statistical Manual, Fourth Edition, Text Revised) chronic
schizophrenia.
Methods: Data were pooled from moderately to severely ill patients (n = 1494) from 6 randomized, double-blind
trials (N = 2543). Response was defined as a ≥30% reduction in Positive and Negative Syndrome Scale (PANSS)
Total score by Week 8 of treatment. Analyzed predictors were change in individual PANSS items at Weeks 1 and 2.
A decision tree was constructed using classification and regression tree (CART) analysis to identify predictors that
most effectively differentiated responders from non-responders.
Results: A 2-branch, 6-item decision tree was created, producing 3 distinct groups. First branch criterion was a 2-
point score decrease in at least 2 of 5 PANSS positive items (Week 2). Second branch criterion was a 2-point score
decrease in the PANSS excitement item (Week 2). “Likely responders” met the first branch criteria; “likely non-
responders” did not meet first or second criterion; “not predictable” patients did not meet the first but did meet
the second criterion. Using this approach, response to treatment could be predicted in most patients (92%) with
high positive predictive value (79%) and high negative predictive value (75%). Predictive findings were confirmed
through analysis of data from 2 independent trials.
Conclusions: Using a data-driven approach, we identified decision rules using early change in the scores of
selected PANSS items to accurately predict longer-term treatment response or non-response to atypical
antipsychotic therapy. This could lead to development of a simple quantitative evaluation tool to help guide early
treatment decisions.
Trial Registration: This is a retrospective, non-intervention study in which pooled results from 6 previously
published reports were analyzed; thus, clinical trial registration is not required.
Background
Over 66% of patients with chronic schizophrenia who
are started on atypical antipsychotics for treatment of
moderate to severe symptoms will fail to show moderate
improvement after 3 months of treatment, and 1 in 3
will fail to show even minimal improvement [1,2].
When treatment does not rapidly bring about sympto-
matic improvement, patients have less long-term func-
tional progress, higher health care costs, and a reduced
likelihood of remission [3]. These patients are more
likely to discontinue treatment compared to those who
experience rapid improvement [4], and treatment dis-
continuation can have devastating consequences in this
population [5]. The ability to rapidly identify patients
who are unlikely to improve on a given treatment allows
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schedule of delivery, an alternative medication) that could
lead to better symptomatic relief, increased treatment
adherence, decreased burden of suffering for patients and
families, and decreased health care resource utilization.
Until recently, scientists and clinicians believed that at
least 3 to 4 weeks of treatment were needed for patients
to experience clinically meaningful symptomatic
improvement in response to antipsychotic therapy. It
has now been convincingly shown that a substantial
amount of improvement occurs within 2 weeks or less
of initiating treatment [6-8]. Failure to respond within
this time frame has been shown in multiple post hoc
analyses to strongly predict later non-response with con-
tinued use of the same agent [1,9,10]. More recently, the
predictive power of early response/non-response was
shown in a prospective study of patients with chronic
disease [2] and in a retrospective study of patients
experiencing first episode psychosis [11].
To date, studies assessing early symptom improvement
[1,2,9,10] as a predictor of longer-term response have
used a predetermined percent reduction from baseline in
the Brief Psychiatric Rating Scale (BPRS) [12] Total score
or the Positive and Negative Syndrome Scale (PANSS)
[13] Total score at a point early in treatment as the cri-
terion for differentiating likely responders and likely non-
responders; for example, a 20% improvement in PANSS
Total score at Week 2 of treatment might identify
patients likely to respond at Week 8. However, the BPRS
and PANSS are rarely used in clinical practice. The BPRS
consists of 18 items and requires 20 to 30 minutes to
administer, and the PANSS consists of 30 items and
takes up to 40 minutes to administer. Time constraints
related to patient care make using these scales to guide
clinical decision making all but impossible.
I nt h i ss t u d yw eu s e dd a t af r o m6r a n d o m i z e d ,d o u -
ble-blind clinical trials of atypical antipsychotic medica-
tions for treatment of moderately to severely ill patients
with chronic schizophrenia to develop a simple decision
tree employing early symptom improvement to predict
longer-term response to treatment. Specifically, we used
classification and regression tree (CART) analysis
[14,15] to identify what amount of change in which of
the fewest PANSS symptom measures at the earliest time
in treatment is most predictive of response or non-
response at Week 8 of treatment. Once a decision tree
was created, we tested its validity by applying it to pre-
dict response in 2 independent studies with similar
designs and patient populations.
Methods
Patients
Data from patients who met criteria for moderate to
severe illness (n = 1494) were pooled from 6 randomized,
double-blind trials of at least 8 weeks duration that com-
pared atypical antipsychotics in the treatment of adult
patients with chronic schizophrenia (N = 2543). In 5 of
the studies, olanzapine was compared to another atypical
antipsychotic: risperidone in 2 trials [16,17]; ziprasidone
in 2 trials [18,19]; and quetiapine in 1 trial [20]. One of
these studies included randomization to haloperidol treat-
ment [16], but data from this arm were not included in
this analysis since we were constructing a decision tree
pertaining only to atypical antipsychotics. In the sixth
study, 3 fixed doses of olanzapine were used to assess the
dose-response relationship of standard and higher-dose
olanzapine [21]. All studies assessed efficacy and safety
outcomes, and they ranged in duration from 8 to
52 weeks. For consistency, all analyses were limited to
data through 8 weeks of treatment, the duration of the
shortest study. Also, to ensure that the final model accu-
rately reflected the clinical course of patients with chronic
illness who have positive symptoms and are moderately
to severely ill at presentation, the analysis was limited to
data from patients who had a PANSS Total score ≥75
and a score ≥4o na tl e a s t2o ft h e4B P R Sp o s i t i v es y m p -
tom items (conceptual disorganization; suspiciousness;
hallucinatory behavior; and unusual thought content)
(n = 1494).
All participants met Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition, Text Revised
(DSM-IV TR) criteria for schizophrenia, schizophreni-
form disorder, or schizoaffective disorder, with the
majority of patients having been diagnosed with schizo-
phrenia. The mean patient age was between 35 and
45 years, mean duration of illness was >10 years, and
the group mean PANSS Total scores were ≥75. Patients
in 3 of the studies [16,19,20] had lower PANSS Total
scores (range: 85-86), while the other 3 studies [17-19]
enrolled patients who were more acutely ill (baseline
PANSS Total range: 95-102). Two studies had a special
focus: the first enrolled patients with prominent depres-
sive symptoms [19], and the other enrolled patients with
prominent negative symptoms [20]. Patient populations
were otherwise very similar across all studies.
Data from the 6 pooled studies is hereafter referred to
as the “learning data set.” The learning data set was
used to create the decision tree, which was intended for
future use in predicting response to treatment for simi-
lar patients.
Once the decision tree had been developed, it was
validated using 2 independent studies. The first was a
12-week prospective trial to assess whether early symp-
tom change in response to risperidone could predict
subsequent clinical and functional outcomes in patients
with schizophrenia [2]. The second was a 28-week, ran-
domized, double-blind comparator trial of olanzapine
versus aripiprazole for treatment of schizophrenia [22].
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Page 2 of 11Patients in these 2 studies were similar to those in the
learning data set. The majority of patients in these stu-
dies were aged late 30 s to early 40 s, had been ill with
schizophrenia for >15 years, and were moderately to
severely ill at baseline, with mean PANSS Total scores
in the 90 to 95 range.
All study protocols were approved by the respective
ethical review boards at participating study sites and
were conducted in accordance with Good Clinical Prac-
tice and the Declaration of Helsinki guidelines. All
patients or their legal guardians gave written informed
consent prior to undergoing any study procedure or
receiving any study treatment. The 6 pooled studies and
2 validation studies are summarized in Table 1. Detailed
descriptions are available in their respective published
reports [2,16-22].
Assessments and Definitions
In studies from the learning data set and the 2 trials
used to assess the validity of the final model, patients
had been evaluated at baseline and at all subsequent vis-
i t s( W e e k s1 ,2 ,3 ,4 ,6 ,a n d8 )u s i n gt h eP A N S S 1-7,a
30-item rating instrument of positive, negative, and gen-
eral psychopathology symptoms (each item scored from
1=a b s e n tt o7=s e v e r e )a n dt h eC l i n i c a lG l o b a l
Impression-Severity (CGI-S) scale [23], a clinician
assessment of overall severity of illness (scored from 1 =
normal, not at all ill to 7 = extremely ill). The Heinrich
Quality of Life scale (QLS) [24], a 21-item, physician-
rated scale designed to assess functional outcomes in
patients with schizophrenia, was administered at Weeks
1 and 8. Each item of the QLS is rated on a 7-point
scale (0-6), and total scores range from 0 to 126, with
higher scores indicating less functional impairment.
Response was defined as a ≥30% reduction from baseline
in PANSS1-7 Total score by Week 8 of treatment, a thresh-
old chosen to reflect symptom improvement that was bet-
ter than “minimal”[8], yet still realistic at this early time
point. Patients with ≥30% improvement at Week 8 were
identified as responders; those with <30% improvement at
Week 8 were identified as non-responders. Missing data
from each of the studies were handled by the method of
last-observation-carried-forward (LOCF).
Statistical Analysis
Construction of Decision Tree
We used CART analysis to determine which individual
components of symptom improve m e n t( i n p u tv a r i a b l e s )
were most predictive of longer-term response. In CART
analysis, a set of rules is developed for dividing a large het-
erogeneous population into smaller, more homogeneous
groups with respect to a particular target variable [25]. For
this analysis, the target was response to treatment, as pre-
viously defined. The division or branching process was
accomplished by searching all input variables (ie, potential
predictors) and all values of each input variable to find the
individual variable and its cut-off value that best classified
patients as responders or non-responders, as determined
by some statistical criteria. For each subgroup identified
by the first branching step, the process was repeated,
creating a tree structure known as a classification tree or
decision tree. Input variables were absolute PANSS symp-
tom scores at baseline and change from baseline in indivi-
dual symptom scores at Weeks 1 and 2. Baseline
characteristics such as gender, age, and illness duration
were also included as input variables. Several input vari-
ables produced similar decision trees, and combining
symptom scores that were highly correlated allowed us to
form composite variables that had greater predictive
power. Examples included “at least a 2-point drop in
symptom 1 and symptom 2.” The amount of change, the
composition of symptoms, and the number of symptoms
included in the composite variable were explored broadly.
Once the final composite input variable was chosen, we
limited branching of the resulting decision tree in an effort
to create a simple tool that could be used in clinical prac-
tice. Consideration was given to how much additional
accuracy a partition added to the entire tree to warrant
the complexity that resulted from having added it.
Assessing Validity
To ensure that our results were not driven by any one
study or compound, we applied the model to data from
the learning data set stratified by study and by compound,
and calculated the positive predictive value (PPV), negative
predictive value (NPV), percent not predictable, and per-
centage of patients who were misidentified (predicted to
be a responder, but did not respond, or predicted not to
respond, but did respond) for each subgroup.
To ensure that our Week 8 threshold for response –
≥30% improvement in PANSS1-7 Total score – had not
unduly affected the final tree, we repeated the analysis
using thresholds for response of ≥20% and ≥40%
improvement. Finally, we calculated PPV, NPV, and per-
centage not predictable using the same degree of change
in PANSS items from the final model, but with timing
of that change defined by week of treatment (Weeks 1,
2, 4, 6, and 8) to ensure that a reasonable time point to
assess early improvement had been chosen.
To assess the degree to which the criteria identified at
Week 2 could accurately predict response beyond Week
8, we applied the model to data from Weeks 12 and 24
that were pooled from the 5 studies in the learning
dataset lasting ≥24 weeks.
To assess the external validity of the tree, we applied it
to data from 2 independent studies with similar patient
populations and calculated the resulting PPV, NPV, per-
centage not predictable, and percentage of patients
misidentified.
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Page 3 of 11Table 1 Characteristics of the 6 Studies Comprising the Learning Dataset and the 2 Studies Used for Validation of the CART-derived Decision Tree
Discontinuation
Rate, n (%)
Study Duration
(weeks)
Design Outcomes Compounds N n
(%)
Inclusion Criteria Through
Week 2
Through
Week 8
Learning Data Set Studies
Keefe
[16]
52 Double-
blind
Randomized
Controlled
Flex-dose
Neurocognitive;
Psychosocial;
Efficacy;
Safety
Olanzapine
Risperidone
159
158
148
(47%)
Schizophrenia or schizoaffective disorder
Inpatient and outpatient
Age 18 to 65
Score ≥18 on the BPRS (ext) and ≥4o n≥2 positive items of the PANSS
19 (11%)
16 (10%)
24 (14%)
32 (19%)
Tran
[17]
28 Double-
blind
Randomized
Controlled
Flex-dose
Efficacy;
Safety
Olanzapine
Risperidone
172
167
227
(67%)
Schizophrenia, schizophreniform disorder, schizoaffective disorder
Inpatient and outpatient
Age 18 to 65
BPRS (ext) score ≥42
15 (9%)
21 (13%)
32 (20%)
29 (18%)
Breier
[18]
28 Double-
blind
Randomized
Controlled
Flex-dose
Efficacy;
Safety
Olanzapine
Ziprasidone
277
271
122
(22%)
Schizophrenia
Inpatient and outpatient
Age 18 to 75
Scores ≥42 on the BPRS (ext), ≥4o n≥1 positive symptom item of the PANSS, and CGI-S
rating ≥4 (moderately ill)
27 (10%)
48 (18%)
39 (14%)
52 (19%)
Kinon
[20]
24 Double-
blind
Randomized
Controlled
Flex-dose
Negative Symptoms;
Functional Outcome;
Efficacy;
Safety
Olanzapine
Quetiapine
171
175
142
(41%)
Schizophrenia, schizoaffective disorder
Outpatient
Age 18 to 65
Score ≥4o n≥3, or ≥5o n≥2 of the 7 negative symptom items of the PANSS, and ≤60
(moderate difficulties) on the GAF
13 (8%)
17 (10%)
39 (23%)
44 (25%)
Kinon
[19]
24 Double-
blind
Randomized
Controlled
Fixed-dose
Depressive
Symptoms;
Efficacy;
Safety
Olanzapine
Ziprasidone
202
192
62
(16%)
Schizophrenia, schizoaffective disorder
Inpatient and outpatient
Age 18 to 60
Scores ≥16 (mild depression) on the MADRS and ≥4 (pervasive feelings of sadness or
gloominess) on item 2 (reported sadness) of the MADRS
23 (11%)
31 (16%)
49 (24%)
63 (33%)
Kinon
[21]
8 Randomized
Double-
blind
Fixed-dose
Dose-response
relationship;
Efficacy;
Safety
Olanzapine
10 mg
20 mg
40 mg
199
200
200
486
(81%)
Schizophrenia or schizoaffective disorder Suboptimal treatment on present antipsychotic,
but not treatment resistant
83 (14%) 109 (18%)
Validation Studies
Kinon
[2]
12 Prospective
Randomized
Double-
blind
Flex-dose
Parallel
Early improvement
predictive of later
response
Risperidone 628 438
(70%)
Schizophrenia, schizophreniform disorder, schizoaffective disorder
BPRS Total ≥45; score of ≥4 (moderate) on at least two of the following BPRS items:
conceptual disorganization, suspiciousness, hallucinatory behavior, and unusual thought
content; CGI-S rating ≥4 (moderately ill)
Exacerbation of illness within two weeks of Visit 1
3 (1%) 127 (24%)
Kane
[22]
28 Double-
blind
Randomized
Controlled
Flex-dose
Efficacy
Safety
Olanzapine
Aripiprazole
281
285
415
(73%)
Schizophrenia
Age 18 to 65 years
Initial PANSS Total score ≥75; score of ≥4 on one of the PANSS positive, and score of ≥4
on the CGI-S; score of ≥3 on the CGI-I at Visit 2.
27 (10%)
39 (14%)
44 (16%)
48 (17%)
Abbreviations: BPRS (ext) = Brief Psychiatric Rating Scale extracted from the PANSS; CART = classification and regression tree; CGI-I = Clinical Global Impression-Improvement; CGI-S = Clinical Global Impression-
Severity; GAF = Global Assessment of Functioning; MADRS = Montgomery-Asberg Depression Rating Scale; N = total number of patients within each treatment group for each study; n (%) = number and proportion
of patients from each study who met illness severity criteria for inclusion in this analysis; PANSS = Positive and Negative Syndrome Scale.
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1Baseline and Visit-wise Assessment of Predicted Response
Groups
Baseline characteristics of likely responder, likely non-
responder, and not predictable groups were compared
using analysis of variance (ANOVA) and the Cochran-
Mantel-Haenszel test accounting for study effect. Visit-
wise mean PANSS Total scores were compared by
group using ANOVA adjusted for study at each time
point. As a validation of results obtained using PANSS
scores, we analyzed by group the distribution of CGI-S
categories (normal to mild [1-3], moderate [4], and
marked to extreme [5-7]) at each visit using Fisher’s
exact test. Changes in QLS score from baseline to Week
8 were compared between groups using ANOVA
adjusted for study effect.
Results
Construction of Decision Tree
Exploratory analyses consistently showed that the key
predictors of response were whether a patient had at
least a 2-point drop in any 1 of the following 5 items
from the PANSS Positive subscore: 1-Delusions; 2-
Conceptual Disorganization; 3-Hallucinatory Behavior;
6-Suspiciousness; and 23-Unusual Thought Content.
A single composite variable was identified as the optimal
first partition splitting-variable: at least a 2-point drop in
at least 2 of these items.
The final decision tree for predicting longer-term
response to treatment based on early symptom improve-
ment involved 2 branches and 3 predicted outcome
groups: likely responders, likely non-responders, and not
predictable (Figure 1). At the first level, patients were
partitioned based on whether they had improved by at
least 2 points on at least 2 items of the composite vari-
able at Week 2. Patients who met this criterion were
identified as likely responders. Patients who did not
meet this criterion were further partitioned based on
whether they had improved by at least 2 points on the
excitement item (4-Excitement) at Week 2. Patients who
met neither the first nor second level criteria were iden-
tified as likely non-responders; patients who did not
meet the first branch criterion, but met the second
branch criterion were identified as not predictable.
The decision tree applied to the learning data set is
illustrated in Figure 2. Of the 1494 patients in the learn-
ing data set, 644 (43%) ultimately demonstrated
response, defined as a ≥30% improvement in PANSS
Total score at Week 8. Using the first branch criterion,
445 patients were identified as likely responders, of
which 352 actually responded (PPV = 79%). Of the 1049
patients who did not meet the first branch criterion, 755
ultimately did not respond (NPV = 72%). The NPV
could be improved further by using the second branch
criterion to separate the 1049 patients into likely non-
responders and not predictable. Of the 929 patients who
did not meet first and second branch criteria at Week 2,
698 did not respond (NPV = 75%). The number of
patients in whom a prediction could not be made was
small (120/1494 = 8%). Of the 24% (326/1374) of
patients who were misidentified, 95 were non-
responders who had been identified as likely responders,
and 231 were responders who had been identified as
likely non-responders.
Week 8 response was predicted more accurately by
improvement in individual PANSS items at Week 2 than
by improvement at Week 1 or by baseline characteristics.
We also investigated the predictive value of the CGIS
score at Week 2 as a single variable for predicting later
response. A 2-point drop in CGI-S at Week 2 resulted in a
PPV of 83% and an NPV of only 56%. Since only a small
proportion of patients (5.7%) had this level of improve-
ment by Week 2, we also calculated the predictive charac-
teristics of a 1-point drop in CGI-I score, a level of
improvement achieved by 49% of patients. The results – a
PPV of 67% and a NPV of 60% – indicated that this degree
of change in this variable was a far less reliable predictor of
later response than change in a cluster of PANSS Positive
symptoms at that same point in time.
Assessing Validity
With regard to differences across studies (Table 2), the
range of PPVs (46% to 85%) and NPVs (60% to 95%)
was fairly wide, reflecting the variation in results known
to exist between trials of antipsychotic agents. However
the PPVs and NPVs were distributed evenly across their
respective ranges, and there was no single outlier that
pulled results in one direction or the other. Concerning
consistency across compounds (Table 3), PPVs were
consistently high (66% to 82%), except for the PPV seen
in the study in which quetiapine was the comparator
(40%). We believe that this difference may be explained
AllPatientsinData
Set
Improvementofatleast2pointsontwooffive
iti it t W k 2? positiveitemsatWeek2?
LikelyResponder Improvementofatleast2pointson
hi i W k 2 ?
YES NO
Likely NotPredictable
theexcitementitematWeek2?
NO YES
NonͲresponder
Figure 1 Final CART-derived decision tree for early symptom
change predicting later response. Response is defined as ≥30%
improvement from baseline in PANSS Total score at Week 8.
Abbreviations: PANSS = Positive and Negative Syndrome Scale.
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Page 5 of 11by the slower rate of response seen for patients in this
trial. In this trial, recruited patients had prominent
negative symptoms, a clinical characteristic associated
with poor response to antipsychotics. Also, this trial
employed a slower rate of titration than was used in the
other studies. Even with these differences, the ratios of
patients meeting response criteria at Week 2 to patients
meeting criteria at Week 8, that is, the post-test to pre-
test ratios, were very similar between the quetiapine
study (40%/20% = 2) and the pooled studies (79%/43% =
1.8), suggesting that the model developed in this analysis
was consistent, regardless of the rate of response at
AllPatientsinDataSet
N=1494
Responders:43%
NonͲresponders:57%
Improvementofatleast2pointsontwooffive
positive items at Week 2? positiveitemsatWeek2?
n=1049 LikelyResponder
Yes No
Responders:28%
NonͲresponders:72%
n=445
Responders:79%
NonͲresponders:21%
Improvement of at least 2 points on the Improvementofatleast2pointsonthe
excitementitematWeek2?
No Yes
PredictiveCharacteristics
PPV:79%
NPV:75%
NotPredictable
n=120
Responders:53%
NonͲresponders:47%
Likely
NonͲresponder
n=929
Responders:25%
d%
Notpredictable:8%
Misclassified:24%
NonͲresponders:75%
Figure 2 Final CART-derived decision tree for early symptom change predicting later response, learning data set. Response is defined as
≥30% improvement from baseline in PANSS Total score at Week 8. Abbreviations: PANSS = Positive and Negative Syndrome Scale.
Table 2 CART-derived Decision Tree Outcomes for the
Learning Data Set and its Component Studies
Positive
Predictive
Value
Negative
Predictive
Value
Not
Predictable
Misidentified
Learning Data Set 79% 75% 8% 24%
Keefe[16]
(n = 148)
46% 95% 5% 14%
Tran[17] (n = 227) 76% 60% 9% 35%
Breier[18]
(n = 122)
85% 68% 12% 25%
Kinon[19]
(n = 142)
63% 81% 8% 24%
Kinon[20]
(n = 52)
58% 89% 5% 16%
Kinon[21]
(n = 486)
84% 72% 6% 23%
Abbreviations: CART = classification and regression tree.
Table 3 CART-derived Outcomes for the Learning Data
Set and its Component Compounds
Positive
Predictive
Value
Negative
Predictive
Value
Not
Predictable
Misidentified
Learning Data
Set (n = 1494)
79% 75% 8% 24%
Olanzapine
(n = 1005)
81% 73% 8% 26%
Quetiapine
(n = 71)
40% 88% 6% 19%
Risperidone
(n = 185)
66% 77% 7% 26%
Ziprasidone
(n = 233)
82% 78% 9% 21%
Abbreviations: CART = classification and regression tree.
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Page 6 of 11Week 2. NPVs by compound (range 73% to 88%) fell
within a 15-point range, with no outliers present.
A slow rate of response would have had greater impact
on PPV than on NPV.
A sensitivity analysis using ≥20% and >40% thresholds
for response at Week 8 resulted in similar trees pro-
duced using a >30% threshold, except that only a 1-
point improvement in each of the identified PANSS
items was needed when the lower threshold was used.
Of the 1008 patients pooled from the 5 studies lasting
≥24 weeks, 41% and 43% of patients demonstrated a
40% reduction in PANSS Total score at Weeks 12 and
24, respectively. When model criteria were used to pre-
dict response at Weeks 12 and 24, the PPVs were 71%
and 51%, respectively and the NPVs were 86% and 82%,
respectively. These results were only slightly less robust
than those observed with the learning dataset (PPV =
79% and NPV = 75%).
The percentage of patients who demonstrated a ≥30%
response by Week 8 in the 2 independent validation stu-
dies was 37.1% for Kinon et al. [2] and 46.7% for Kane
et al. [22], which were similar to that of patients who
achieved this degree of response in the pooled studies
(also 42%). The predictive accuracy of the decision tree
applied to each of the independent studies was highly
consistent with that seen for the learning data set (PPV =
70% and 77%, respectively; NPV = 77% and 68%, respec-
tively) (Table 4).
Positive predictive value and NPV using the described
1-branch and 2-branch decision tree models, and the
percentage of patients in the learning data set who were
not predictable are shown by week of treatment in Fig-
ure 3. Although the range of PPV throughout the study
was narrow, it peaked at Week 2 (79%), after which it
fell to a low of 71% at Week 6. In contrast, regardless of
whether the 1-branch or 2-branch decision tree was
used, NPV gradually increased throughout the study.
Using the 2-branch model, NPV was 65%, 75%, 85%,
and 86% for Weeks 1, 2, 4, and 6, respectively.
Baseline and Visit-wise Assessment of Predicted Response
Groups
Baseline characteristics and illness severity for likely
responder, likely non-responder, and not predictable
groups are shown in Table 5. A significantly greater
proportion of patients identified as likely responders or
not predictable were female compared to patients identi-
fied as likely non-responders (p = .02). Compared to likely
non-responders, these 2 groups were also more likely to
have had higher illness severity as measured by PANSS
Total (p < .001), PANSS Positive (p < .001), PANSS Nega-
tive (p = .002), and CGI-S (p < .001) scores at baseline.
Visit-wise mean PANSS Total score for patients in the
learning data set are shown in Figure 4. As had been
seen in previous response prediction studies [2,11], the
reduction in mean PANSS Total score was significantly
lower (p < .001) at every post-baseline visit for likely
responders compared to likely non-responders.
A separation between group means was evident as early
as Week 1 and this gap widened by Week 2, at which
time likely responders had a 32-point improvement,
4 times that seen in likely non-responders. The profile
of mean PANSS score over time for the not predictable
group lay between those of the other 2 groups. The per-
centage of patients with CGI-S scores indicating normal
to mild (1-3), moderate (4), and marked to extreme
(5-7) illness severity is s h o w no v e rt i m eb yo u t c o m e
group in Figure 5. By study end, 72% of likely respon-
ders had normal to mild symptoms compared to 49% in
the not predictable group and 45% in the likely non-
responder group (p < .001). Mean improvement from
baseline to Week 8 in QLS Total scores was 13.8, 7.1,
and 3.7 points for the likely responder, not predictable,
and likely non-responder groups, respectively (p < .001).
Discussion
We used CART analysis on data pooled from 6 large,
double-blind, randomized atypical antipsychotic therapy
Table 4 CART-derived Decision Tree Outcomes for the
Learning Data Set and Validation Studies
Positive
Predictive
Value
Negative
Predictive
Value
Not
Predictable
Misidentified
Learning Data Set 79% 75% 8% 24%
Kinon[2] 70% 77% 7% 25%
Kane[22] 77% 68% 7% 29%
Abbreviations: CART = classification and regression tree.
Figure 3 PPV and NPV using one- and two-branch decision
tree models. Percentage of patients identified as not predictable as
determined using decision tree rules, but with response defined by
week of treatment. Abbreviations: NVP = negative predictive value;
PPV = positive predictive value.
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Page 7 of 11trials to develop a simple 2-branch decision tree that
uses the amount of improvement in 6 PANSS items
after 2 weeks of treatment to predict the likelihood of
longer-term response to continued use of the same treat-
ment by Week 8. When the model was applied to the
data set from which it was created, we identified likely
responders with 79% accuracy, likely non-responders with
75% accuracy, and a small group of patients (8%) in
whom a prediction could not be made. In analyses of the
3 predicted response groups, patients identified as likely
responders were more commonly female and had a
shorter duration of illness than likely non-responders.
They were also more severely ill at baseline across a spec-
trum of symptom domains, and showed significantly
more rapid and more pronounced improvement over
time.
At the first branch of the decision tree, patients were
assessed for improvement in a composite variable
Table 5 Baseline Demographics and Illness Severity for Predicted Outcome Groups
Likely Responders Likely Non-responders Not Predictable p-value
a
n (%) 445/1494 (29.8) 929/1494 (62.2) 120/1494 (8.0)
Age in years, mean (SD) 39.1 (11.1) 40.4 (10.6) 38.9 (10.4) .06
Female gender, n (%) 167 (37.5) 295 (31.8) 51 (42.5) .02
Ethnicity/Race, n (%)
White 219 (49.2) 474 (51.0) 56 (46.7) .53
Black 141 (31.7) 309 (33.3) 43 (35.8)
Hispanic 85 (19.1) 146 (15.7) 21 (17.5)
Diagnosis, n (%)
Schizophrenia 345 (77.5) 743 (80.0) 101 (84.2) .26
Schizoaffective disorder 95 (21.3) 186 (20.0) 18 (15.0) .31
Schizophreniform disorder 5 (1.1) 0 (0.0) 1 (0.8) .003
Age at illness onset in years, mean (SD) 23.8 (8.8) 23.4 (8.3) 23.0 (7.4) .53
Duration of illness in years, mean (SD) 15.3 (10.9) 17.0 (10.7) 15.9 (10.5) .02
Number of prior episodes, median 5 6 5
PANSS Total score, mean (SD) 101.5 (16.1) 95.4 (14.0) 101.9 (17.3) <.001
PANSS Positive score, mean (SD) 25.6 (5.1) 23.5 (4.2) 26.1 (4.7) <.001
PANSS Negative score, mean (SD) 26.0 (5.9) 24.9 (5.5) 25.4 (6.0) .002
CGI-S score, mean (SD) 4.8 (0.8) 4.7 (0.7) 4.8 (0.7) <.001
Weight in kg, mean (SD) 83.0 (22.9) 84.9 (20.5) 82.6 (22.0) .24
Abbreviations: CGI-S = Clinical Global Impression-Severity
23; n = number in group; PANSS = Positive and Negative Syndrome Scale
13; SD = standard deviation.
aComparisons based on analysis of variance (ANOVA) and the Cochran-Mantel-Haenszel test accounting for study effect.
Figure 4 Visit-wise mean PANSS Total scores.P e r c e n t a g eo f
patients in the learning data set identified as likely responders, likely
non-responders, and not predictable using decision tree rules.
Abbreviations: PANSS = Positive and Negative Syndrome Scale.
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Page 8 of 11consisting of 5 of the PANSS Positive items. A separate
analysis of individual PANSS items showed strong cor-
relation between these 5 items, lending strength to our
model. Several other prediction studies have identified
early improvement in positive symptoms as the primary
predictor of later response and non-response. Correll
et al [9] evaluated BPRS scores as a predictor of later
non-response and identified lack of improvement in the
thought disturbance factor as the strongest predictor of
non-response. Similarly, in 2 studies in which early
improvement in PANSS Total score was shown to be
predictive of later response [1,2], 40% of the overall
improvement was due to the PANSS Positive subscore,
with the other subscores contributing only 27% to 33%
of the improvement.
Finding that early improvement in positive symptoms
accurately predicted later improvement confirmed
results of earlier studies and extended these results by
specifying how early improvement can be assessed and
how much improvement is required to accurately pre-
dict later response. We focused on a population of
patients with chronic schizophrenia who were moder-
ately to severely ill, with predominantly positive symp-
toms. This describes the majority of patients who come
to medical attention and who are initiated or re-initiated
on antipsychotic treatment, or who have their current
medication changed or adjusted. Also, antipsychotics are
most effective in treating positive symptoms, so a model
that predicts later response based on early response is
likely to include them. Whether this model applies to
patients without prominent positive symptoms will be
an interesting area for future research.
Our decision tree was strengthened and stabilized by
the large number of patients and the diversity of studies
pooled to create our data set. Although each of the stu-
dies had a similar design and similar enrollment criteria,
they were carried out at both U.S. and international
sites, included 5 different atypical antipsychotics, and
were completed over an 11-year period. An analysis of
model performance by study and by compound sug-
gested that the creation of the model had not been dri-
ven by any one study or any one compound, but rather
was a reasonable reflection of its component parts.
Many strategic decisions are made during a CART
analysis, and the final usefulness of a classification tree
depends heavily on the skill and judgment of the statisti-
cians, scientists, and clinicians who determine the input
variables and prune the output. We chose changes in
PANSS item scores obtained at Weeks 1 and 2 as input
variables based on prior work with prediction models.
Our analysis of PPV and NPV by study week illustrates
the trade-offs inherent in choosing the time for early
assessment. While PPV stayed relatively stable regardless
of the time point chosen, NPV improved as treatment
time passed. However, in the clinical setting, delaying a
treatment decision in order to improve NPV translates
into additional suffering for some patients who will not
improve on present therapy, so we included only very
early time points as input variables. We also chose indi-
vidual PANSS items as input variables rather than the
PANSS Total score. The practicality of using a tool con-
sisting of only 6 questions rather than administering the
entire 30-question PANSS cannot be overemphasized.
Pruning is another area where investigator input is
required. A decision tree that is too complex will likely
reflect the idiosyncrasies of the data set used to create
i t ,w h i l eat r e et h a ti st o os i m p l em a yn o tf i ta n yd a t a
set very well. In constructing this decision tree, we con-
sidered pruning back to the first branch, at which point
t h eN P Vw a s7 2 % .B yi n c l u d i n gt h ea d d i t i o n a lb r a n c h ,
we improved the NPV to 75%, but in doing so, added
another level of complexity to what could have been a
single-question algorithm. This balance between com-
plexity and increased predictive value must be weighed
by the practicing clinician.
We found that our model was more accurate in pre-
dicting response at Week 8 based on response at Week
2 than change in the CGI-I at Week 2. Accurate predic-
tion of later response may require a careful assessment
of the current severity of a few distinct symptoms rather
than a summary measure of change over 2 weeks that
includes consideration of the patient’s history, psychoso-
cial circumstances, symptoms, behavior, and functioning.
Constructing a decision tree using CART analysis
requires having access to a very large database with a
consistent set of patients (eg, similar inclusion/exclusion
criteria), consistent study design (eg, timing, blinding,
randomization), and consistent clinical measurements
(eg, PANSS). With the appropriate database, CART ana-
lysis is a powerful method for answering clinical ques-
tions. It is non-parametric; that is, no assumptions are
made regarding the underlying distribution of variables,
and it permits consideration of both continuous and
categorical data. It can handle data sets with large num-
bers of input variables, each with many possible values;
identify significant high-order interactions among vari-
ables; detect and quantify non-linear relations; deter-
mine which predictors can be dropped because they
contain redundant information; and handle missing
values through a process of “surrogate substitution.”
The tree can be simplified because the response vari-
ables are, for the most part, conditionally independent
of variables not in the tree. CART analysis is limited in
that it can be unstable; that is, a small change in the
input variables or a fresh data sample can lead to con-
struction of a very different classification tree. In addi-
tion, CART analysis is limited in that it can account for
only one response variable [14,15].
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likelihood of response) is in line with the mindset of
most clinicians. After initiating treatment, clinicians rou-
tinely evaluate their patients, make judgments about
their progress, and decide whether they should continue
treatment or make a change. This decision tree simply
provides evidence-based tools, an algorithm, and asso-
ciated PPV and NPV, to help quantify the decision-mak-
ing process. Clinicians must still actively consider the
unique presentation of each patient; for example, a
patient with a high probability of failure as determined
by the algorithm may benefit from continuing the treat-
ment if they have already failed several previous medica-
tions and a patient with a high probability of success
may have treatment discontinued due to an intolerable
adverse event.
We recognize that when outcomes have been categor-
ized as dichotomous (response/non-response), other
approaches such as logistic regression can be used to
create a predictive model. The strengths of CART com-
pared with logistic regression are worth noting in this
setting. First, CART analysis offers a great deal of flex-
ibility because it requires very few assumptions about
the data. Due to its natural branching process, CART is
able to handle many dozens of potential predictor vari-
ables as well as potential interactions between predictors
and non-linear effects of individual predictors, and miss-
ing data. CART also has algorithms that account for
missing data amongst the predictors; whereas with logis-
tic regression, entire observations are eliminated if a sin-
gle predictor is missing. Furthermore, at the end of a
CART analysis, subgroups (responders and non-
responders) are specifically defined due to the variable
selection and cut-offs created by the methodology. With
logistic regression, significant predictors are identified,
but the coefficients do not automatically define sub-
groups of patients. Finally, our experience suggests that
the stepwise, dichotomous approach that is used with a
decision tree more closely mimics clinical decision-
making than use of odds ratios which indicate associa-
tion, but do not clearly direct treatment decisions.
Two patient populations identified in our analysis
deserve special attention from a clinical standpoint: first,
the 8% of patients in whom a prediction could not be
made and second, the 24% who were misidentified. The
decision criteria laid out in this model allow for a cate-
gory of patients (those who show improvement in the
excitement item at Week 2, but who do not show signif-
icant improvement in positive symptoms) in whom the
prediction of later response is no better than a coin
toss. Fortunately, this population is relatively small,
<10% in 14 of the 15 analysis subsets (learning data set
analysis, validation analyses, analysis by study, and analy-
sis by compound). Of those patients in the learning data
set who were misidentified, the majority was identified as
non-responders, but eventually did respond. The clinical
ramifications of changing treatment when no change is
needed versus continuing use of an ineffective treatment
must be carefully weighed by all those involved.
Despite having developed this model using response
data from Week 8, the strength of the model was dimin-
ished only slightly when used to predict response at
Weeks 12 and 24. Further research is needed to see if a
model derived using response data following longer-
term treatment data might have greater accuracy in pre-
dicting response beyond Week 8.
Currently, this decision tree is appropriately used
only for adult patients with chronic schizophrenia who
are moderately to severely ill. It needs to be tested in
other patient populations, such as those with chronic
s c h i z o p h r e n i aw h oa r eo n l ym ildly ill, and in patients
with first episode psychosis. In addition, it needs to be
validated in a prospective study design and to be
assessed for inter-rater reliability. It is possible that
introduction of additional variables, functional mea-
surements or patients’ perception of benefit, for exam-
ple, would have altered the final decision tree. Further
model building using data from different populations
and different input variables is needed to establish the
stability of this particular decision tree and to perhaps
construct a tree with even better predictive characteris-
tics and user-friendliness. In addition, were a tool such
as this decision tree to be developed for use in the
clinical setting, input on clear and effective phrasing
would be needed from clinicians. For example, would
verbal descriptions such as “substantial improvement”
or numeric descriptions such as “a 2-point drop” be
most preferred?
Conclusions
We used CART analysis of a large pooled data set to
construct a simple decision tree that was found to be
predictive of later response/non-response based on
improvement in 6 individual PANSS items over 2 weeks
of treatment. These findings could serve as a foundation
for development of a clinically relevant evaluation tool
for guiding treatment decisions early in the course of
atypical antipsychotic drug therapy.
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